Comments
India’s drugs regulator has approved Oxford COVID-19 vaccine Covishield, manufactured by the Serum Institute of India, and indigenously developed Covaxin of Bharat Biotech for restricted emergency use in the country on Sunday, paving the way for a massive inoculation drive.
The Drugs Controller General of India (DCGI) granted the approval on the basis of recommendations by a COVID-19 Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO).
Prime Minister Narendra Modi hailed the approval as a “decisive turning point” in the spirited fight against the pandemic. He added that this would accelerate the process for India to become a COVID-free nation.
He extended his gratitude to doctors, medical staff, scientists, police personnel, sanitation workers, and all ‘‘Corona warriors’‘ for the outstanding work they have done in adverse circumstances, and said the nation will remain eternally grateful to them for saving many lives.
India’s Covid-19 active caseload has dropped below 2.5 lakh today, with the recoveries exceeding new cases and the low number of fatalities per day.
India’s present active caseload consists of just 2.39 per cent of India’s Total Positive Cases. The total coronavirus cases are at 1,03,23,965 and the death toll climbed to 1,49,435 with Covid-19 claiming 217 lives in a span of the last 24 hours.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.